Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A

A. Batorova, A. Boban, M. Brinza, T. Lissitchkov, L. Nemes, I. Zupan Preložnik, P. Smejkal, N. Zozulya, J. Windyga

. 2022 ; 15 (4) : 570-578. [pub] -

Jazyk angličtina Země Rumunsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019000

The next frontier in hemophilia A management has arrived. However, questions remain regarding the broader applicability of new and emerging hemophilia A therapies, such as the long-term safety and efficacy of non-factor therapies and optimal regimens for individual patients. With an ever-evolving clinical landscape, it is imperative for physicians to understand how available and future hemophilia A therapies could potentially be integrated into real-life clinical practice to improve patient outcomes. Against this background, nine hemophilia experts from Central European countries participated in a pre-advisory board meeting survey. The survey comprised 11 multiple-choice questions about current treatment practices and future factor and non-factor replacement therapies. The survey questions were developed to reflect current unmet needs in hemophilia management reflected in the literature. The experts also took part in a follow-up advisory board meeting to discuss the most important unmet needs for hemophilia management as well as the pre-meeting survey results. All experts highlighted the challenge of maintaining optimal trough levels with prophylaxis as their most pressing concern. Targeting trough levels of ≥30-50 IU/L or even higher to achieve less bleeding was highlighted as their preferred strategy. However, the experts had an equal opinion on how this could be achieved (i.e., more efficacious non-factor therapies or factor therapy offering broader personalization possibilities such as targeting trough levels to individual pharmacokinetic data). In summary, our study favors personalized prophylaxis to individual pharmacokinetic data rather than a "one-size-fits-all" approach to hemophilia A management to maintain optimal trough levels for individual patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019000
003      
CZ-PrNML
005      
20220804135245.0
007      
ta
008      
220720s2022 rm f 000 0|eng||
009      
AR
024    7_
$a 10.25122/jml-2022-0103 $2 doi
035    __
$a (PubMed)35646171
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a rm
100    1_
$a Batorova, Angelika $u Department of Hematology and Transfusion Medicine, National Hemophilia Center, Faculty of Medicine of Comenius University and University Hospital, Bratislava, Slovakia $1 https://orcid.org/0000000305674250
245    10
$a Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A / $c A. Batorova, A. Boban, M. Brinza, T. Lissitchkov, L. Nemes, I. Zupan Preložnik, P. Smejkal, N. Zozulya, J. Windyga
520    9_
$a The next frontier in hemophilia A management has arrived. However, questions remain regarding the broader applicability of new and emerging hemophilia A therapies, such as the long-term safety and efficacy of non-factor therapies and optimal regimens for individual patients. With an ever-evolving clinical landscape, it is imperative for physicians to understand how available and future hemophilia A therapies could potentially be integrated into real-life clinical practice to improve patient outcomes. Against this background, nine hemophilia experts from Central European countries participated in a pre-advisory board meeting survey. The survey comprised 11 multiple-choice questions about current treatment practices and future factor and non-factor replacement therapies. The survey questions were developed to reflect current unmet needs in hemophilia management reflected in the literature. The experts also took part in a follow-up advisory board meeting to discuss the most important unmet needs for hemophilia management as well as the pre-meeting survey results. All experts highlighted the challenge of maintaining optimal trough levels with prophylaxis as their most pressing concern. Targeting trough levels of ≥30-50 IU/L or even higher to achieve less bleeding was highlighted as their preferred strategy. However, the experts had an equal opinion on how this could be achieved (i.e., more efficacious non-factor therapies or factor therapy offering broader personalization possibilities such as targeting trough levels to individual pharmacokinetic data). In summary, our study favors personalized prophylaxis to individual pharmacokinetic data rather than a "one-size-fits-all" approach to hemophilia A management to maintain optimal trough levels for individual patients.
650    _2
$a znalecký posudek $7 D005104
650    12
$a hemofilie A $x farmakoterapie $x prevence a kontrola $7 D006467
650    _2
$a krvácení $x prevence a kontrola $7 D006470
650    _2
$a lidé $7 D006801
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Boban, Ana $u Haemophilia Centre, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia $1 https://orcid.org/0000000335322336
700    1_
$a Brinza, Melen $u Centre of Hematology and Bone Marrow Transplant, European Haemophilia Comprehensive Care Centre, Fundeni Clinical Institute, Bucharest, Romania
700    1_
$a Lissitchkov, Toshiko $u Expert Center for Rare Haematological Disorders, Sofia, Bulgaria
700    1_
$a Nemes, Laszlo $u National Haemophilia Centre and Haemostasis Department, Medical Centre of Hungarian Defence Forces, Budapest, Hungary
700    1_
$a Zupan Preložnik, Irena $u Department of Haematology, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/000000019933549X
700    1_
$a Smejkal, Petr $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zozulya, Nadezhda $u National Research Center for Hematology, Moscow, Russia $1 https://orcid.org/0000000170740926
700    1_
$a Windyga, Jerzy $u Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
773    0_
$w MED00196697 $t Journal of medicine and life $x 1844-3117 $g Roč. 15, č. 4 (2022), s. 570-578
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35646171 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135239 $b ABA008
999    __
$a ok $b bmc $g 1822555 $s 1170243
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 15 $c 4 $d 570-578 $e - $i 1844-3117 $m Journal of medicine and life $n J Med Life $x MED00196697
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...